Bacil Pharma (524516) Q4 25/26 earnings summary

Executive summary

• Audited financial results for the quarter and year ended 31 March 2026 were approved, with the company continuing to have no significant operations during the year.

• The audit opinion is unmodified, confirming compliance with Indian Accounting Standards and regulatory requirements.

Financial highlights

• Total revenue for the year ended 31 March 2026 was ₹198.50 lakhs, up from ₹170.62 lakhs year-over-year.

• Net profit before tax for the year was ₹3.89 lakhs, a sharp decline from ₹40.76 lakhs in the previous year.

• Other comprehensive income showed a significant loss of ₹226.30 lakhs due to fair valuation of financial assets.

• Net loss for the year after comprehensive income was ₹164.14 lakhs.

• Cash and cash equivalents at year-end decreased to ₹56.85 lakhs from ₹285.73 lakhs.

Outlook and guidance

• Management expects to restart operations, with current assets exceeding current liabilities and no material uncertainty regarding the company’s ability to meet obligations in the next year.